Activity Overview
The PER Postgame™ is an online, on-demand video
program that brings together renowned experts in the treatment of psoriasis. In
this educational program, faculty explore the evolving science behind psoriasis
management by reviewing pathway targets of small peptides and second-generation
TYK2 inhibitors. The program succinctly interprets recently presented data from
the 2026 American Academy of Dermatology (AAD) meeting on the new and emerging
oral psoriasis treatments that offer promising opportunities to improve patient
quality of life through efficacy, convenience, and safety.
Target Audience
This educational initiative is directed toward dermatologists,
dermatology nurse practitioners, dermatology physician assistants, primary care
physicians, and other health care professionals involved in the diagnosis and
management of psoriasis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe existing treatment gaps and unmet patient needs in the management of psoriasis
- Analyze recent clinical trial efficacy and safety data for emerging oral therapies in psoriasis management
- Explain the mechanisms by which emerging oral psoriasis therapies address current limitations associated with conventional therapies
Jason E. Hawkes, MD, MS
Co-Owner, Chief Scientific Officer, and Investigator
Oregon Medical Research Center
Portland, OR
Clinical Associate Professor of Dermatology,
Oregon Health & Science University
Portland, OR
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Alumis, Apogee, Arcutis, Blueprint Medicines, Bristol Myers Squibb, Dermavant/Organon, Eli Lilly, Galderma, Incyte, Janssen, Kymera Therapeutics, LEO Pharma, Novartis, Oruka, Regeneron, Sanofi, Sun Pharmacutical Industries, Takeda, UCB; Speaker’s Bureau: Alumis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant/Organon, Eli Lilly, Galderma, LEO Pharma, Janssen, Novartis, Regeneron, Sanofi, UCB; Grant/ Research funding: AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Bristol Myers Squibb, Celldex Therapeutics, Concert Pharmaceuticals, Eli Lilly, Incyte, Janssen, Kymera Therapeutics, LEO Pharma, Navigator Medicines, Novartis, Oruka, Pfizer, Priovant Therapeutics, Sanofi, Sun Pharma, Takeda, UCB
Christopher G. Bunick, MD, PhD
Associate Professor
Department of Dermatology
Program in Translational Biomedicine
Institute for Global Health
Yale School of Medicine
New Haven, CT
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Absci, Almirall, Alumis, Amgen, Arcutis, Botanix Pharma, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Disc Medicine, Eli Lilly, EPI Health/Novan, Galderma, Highlight Therapeutics, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer, Priovant, Regeneron, Sanofi, South Beach Symposium, Sun Pharmacutical Industries, Takeda, Teladoc Health, Timber, Triveni, UCB, Veradermics; Grant/Research Funding: AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Palvella, Sun Pharmacutical Industries, Takeda, Timber; Executive Role: Medical Chair, South Beach Symposium
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here